Showing results (161-170 of 1,014) with videos related to
Sort By:
Pageof 102
Biochemical Pharmacology|June 15, 1983
Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigsG Luscombe, P Jenner, C D MarsdenNeuroscience Letters|November 11, 1988
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmosetM Nomoto, P Jenner, C D MarsdenPsychopharmacology|July 6, 1978
The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivityP Jenner, C Pycock, C D MarsdenEuropean Journal of Pharmacology|September 17, 1984
Correlation of [3H]5-hydroxytryptamine (5HT) binding to brain stem preparations and the production and prevention of myoclonus in guinea pig by 5HT agonists and antagonistsG Luscombe, P Jenner, C D MarsdenJournal of Neurochemistry|July 1, 1985
Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitroE Kelly, P Jenner, C D MarsdenNeuroscience Letters|May 1, 1985
Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neuronesE Kelly, P Jenner, C D MarsdenJournal of Neural Transmission. Supplementum|January 1, 1988
Receptor changes during chronic dopaminergic stimulationP Jenner, S Boyce, C D MarsdenClinical Neuropharmacology|April 1, 1997
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesiasF Stocchi, G Nordera, C D MarsdenNeuroscience Letters|October 24, 1994
GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatmentJ Jolkkonen, P Jenner, C D MarsdenPageof 102